Purchased 46,511 shares of common stock in the December 2025 underwritten public offering
| Officer | Age | In this role | Source |
|---|---|---|---|
|
Clay Siegall
Also a director
President, Chief Executive Officer and Chairman of the Board
|
65 | Not stated | |
|
Max Rosett
Chief Financial Officer
|
36 |
Since 2024
2 years
|
|
|
Jack Higgins
Chief Scientific Officer
|
47 |
Since 2023
3 years
|
|
|
Kinney Horn
Chief Business Officer
|
51 |
Since 2024
2 years
|
|
|
Robert Lechleider
Chief Medical Officer
|
65 |
Since 2023
3 years
|
|
|
Sandra Stoneman
Chief Legal Officer and General Counsel
|
53 |
Since 2020
6 years
|
|
|
Philip Tsai
Chief Technical Officer
|
58 |
Since 2024
2 years
|
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchased 46,511 shares of common stock in the December 2025 underwritten public offering
Purchased 150,000 shares of common stock in the January 2025 underwritten public offering
Purchased 1,290,322 shares of common stock in the January 2025 underwritten public offering
Loading...